NCT05462574Recruiting
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension (PAH)
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 14 Jul 2022
- Start date
- 17 Jan 2023
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Vanderbilt University Medical Center
- NCT number
- NCT05462574
What you commit to
- Study type: Observational
- Planned participants: 75
- From 17 Jan 2023 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins
- WHO Functional class IV heart failure
- Patients with implanted/embedded ferromagnetic material that would preclude cardiac MRI
Other
- Pregnancy
- Requirement for continuous oxygen
- Unable to have an MRI/MRS, perform a 6MWD test, or cardiopulmonary exercise test.
Who the study is looking for
- ≥ 18 years old
- Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations.
- Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted.
- WHO Functional Class I-III
- Ambulatory
- Able to have an MRI/MRS, perform a 6MWD test, and cardiopulmonary exercise test
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.